Home Media/Press releases/OREGA Biotech will receive 1.3M€ grant from ANR>
Latest News
See all news


Press release

OREGA Biotech will receive 1.3M€ grant from ANR

Lyon, France, October 5, 2012 – OREGA Biotech, a biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announces today that it has been granted an ANR-RPIB funding from the Agence Nationale pour la Recherche. OREGA Biotech will receive a 1.3M€ grant in order to develop IL-17A neutralizing antibodies for the treatment of some cancer. This funding will allow OREGA Biotech to finance the next phases of its research program up to regulatory toxicology studies.

Download the press release.

See all our press releases

See all events